10:51 AM EST, 11/13/2026 (MT Newswires) -- Zealand Pharma's (ZEAL.CO) Zeydovio received European Commission marketing authorization for the treatment of adults with short bowel syndrome, a rare, chronic and severe disease associated with reduced or complete loss of intestinal function, according to a Friday filing. The approval is backed by the biotechnology company's phase 3 Ease-1 trial, in which the twice-weekly glepaglutide led to a statistically significant greater reduction in parenteral support requirements than placebo among patients with short bowel syndrome and intestinal failure. The approval covers all European Union member states, Iceland, Liechtenstein and Norway, making Zeydovio the first and only ready-to-use GLP-2 therapy to receive regulatory approval

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.